Stock Overview
Camlin Fine Sciences Share Price

Camlin Fine Sciences Share Price

101.68
-1.89 (-1.82%)
11 Sep, 2026 • 03:30 PM
NSE: CAMLINFINE | Chemicals | Small Cap
Buywith MTF at 1x leverage

Camlin Fine Sciences Annualised Returns

1 Year

-51.79%Decrease

3 Years

-15.33%Decrease

5 Years

-9.18%Decrease

10 Years

2.04%Increase

Camlin Fine Sciences Share Price Today


As of 14 Sep 2026, Camlin Fine Sciences share price is ₹101.7. The stock opened at ₹102.6 and had closed at ₹103.6 the previous day. During today’s trading session, Camlin Fine Sciences share price moved between ₹100.89 and ₹102.65, with an average price for the day of ₹101.77. Over the last 52 weeks, the stock has recorded a low of ₹96.21 and a high of ₹235.00. In terms of performance, Camlin Fine Sciences share price has declined by 29.8% over the past six months and has declined by 51.79% over the last year.

Camlin Fine Sciences Stock Performance

1W Return
-1.41%
1M Return
-18.98%
6M Return
-28.71%
1Y Return
-55.02%
3Y Return
-40.51%
Today's High
₹102.65
Today's Low
₹100.89
52-Week High
₹235
52-Week Low
₹96.21
Prev. Close
₹103.57
Open
₹102.57
Face Value
₹1
Mkt Cap (Cr.)
₹1,953
PE Ratio
-56.56

Camlin Fine Sciences Share Price Chart

Camlin Fine Sciences Company background

Founded in: 1993
Managing director: Ashish S Dandekar
Camlin Fine Sciences Limited was originally incorporated on November 30, 1993 as a Private Limited Company with the name of Camlicon Consultants Private Limited. On June 1, 2006, the name of the Company was changed to Camlin Fine Chemicals Private Limited. As per Scheme of Arrangement, the Fine Chemicals Division of Camlin Limited got demerged / transferred to the Company effective from July 01, 2006. On August 11, 2006, the Company status was converted into Public Limited and the name was changed to Camlin Fine Chemicals Limited. W.e.f. 27th August, 2011 name of the Company was again changed from Camlin Fine Chemicals Limited to Camlin Fine Sciences Limited.The Company is one of the Indias leading manufacturers and exporters of Bulk Drugs, Fine Chemicals and Food Grade products. It manufactures active pharmaceutical ingredients (APIs), food antioxidants and sweeteners. They operate in two business divisions, namely Food Ingredients Division and Industrial products Division. The companys products have applications in processed foods, edible oils, paints, polymers, alternative fuels (biodiesel), rubber, health, and pharmaceuticals.In April 2006, the main object of the Company was altered to enable the Company to pursue business in Fine Chemicals. They launched a new product namely, Sucralose which is a synthetic sweetener with large demand and attractive price.The company entered into a joint venture with Viachem LLC USA on 51:49 basis and set up a company namely, Dulcette Technologies LLC for marketing Sucralose, Aspartame and AcesulfameK and their blends in USA, Canada and Mexico. In March 30, 2007, the equity shares of the company were listed on the Bombay Stock Exchange (BSE).During the year 200708, the company increased the production capacity of Chemical Chemical Products from 1,636 Ltrs/Kgs to 2,476 Ltrs/Kgs. The company acquired the control of Sangam Laboratories Ltd by acquiring 60% of the paid up equity share capital of the company. They invested Rs 5 lakh for controlling interest in the Equity Share Capital of Chemolutions Chemicals Ltd. In February 2008, the company entered into a joint venture agreement with Advanced Aerospace Technologies Inc., USA to manufacture and market speciality fine chemicals primarily to cater to European and U.S markets. During the year 200809, the company expanded the production capacity of Chemical Chemical Products from 2,476 Ltrs/Kgs to 2,548 Ltrs/Kgs. The company invested Rs 25.50 lakh in Fine Lifestyle Brands Ltd and Rs.5.10 lakh in Fine Renewable Energy Ltd, which represents 51% of equity share capital of each of them. They further invested Rs 92.32 lakh in the share capital of their present subsidiaries, namely Sangam Laboratories Ltd, Chemolutions Chemicals Ltd and Dulcette Technologies LLC, USA.During the year 200910, the company expanded the production capacity of Chemical Chemical Products from 2,458 Ltrs/Kgs to 3,500 Ltrs/Kgs. They are entering the field of Bio technology products and first patented, biotechnology based Natural shelf life enhancing formula for increasing shelf life of Natural farm produce, like fruits, vegetables and flowers.During the year 2011, Chemolutions Chemicals Limited, Fine Lifestyle Brands Limited and Fine Renewable Energy Limited ceased to be subsidiaries of the Company. The Honble High Court Bombay, vide order dated 21st April, 2011 approved Scheme of Amalgamation for merger of Sangam Laboratories Limited, a 100% owned subsidiary with the Company. The establishment of two major business divisions, namely, Food and Industrial Products was completed. The Company expanded its manufacturing capacity of the food antioxidants, Ascorbyl Palmitate, TBHQ and BHA in 201213. In January 2016, it started operations in Central America with the launch of CFS Antioxidantes De Mexico, S.A. de C.V., a 100% subsidiary of Camlin Fine Sciences Ltd., acquired 65% stake in Dresen Qumica S.A.P.I de C.V, a leading food and feed blend company in Mexico launched CFS North America, LLC, a 100% owned subsidiary of CFS for manufacturing and selling of customised antioxidant blends launched Evanil, ethyl vanillin for food and bakery industry.On 15th April, 2016, a 100% wholly owned subsidiary CFS International Trading (Shanghai) Ltd. was incorporated in China (Shanghai) pilot free trade zone to manufacture and deal in speciality chemicals. On 22nd March, 2017, Chemolutions Chemicals Limited (CCL) allotted 62,67,003 equity shares on preferential basis to the Company. Post allotment, the shareholding of Company in CCL was 94.08% and CCL became the subsidiary of the Company. In July 2017, Company through its wholly owned stepdown subsidiary viz. CFS Europe S.p.A. acquired 51% stake in CFS Wanglong Flavours (Ningbo) Co. Ltd. erstwhile Ningbo Wanglong Flavors and Fragrances Company Limited. In April 2018, Company signed a joint venture contract with Pahang Pharma (S) Pte. Ltd., Singapore (Pahang) for incorporating a holding company, shareholding in the proportion of 51:49, named CFS Pahang Asia Pte. Ltd. in Singapore.In 2019, the Company reverse merged its wholly owned subsidiary in Mauritius viz., CFCL Mauritius Private Limited into CFS Europe Spa, Italy effective 25th June, 2019 and resultant to this merger, CFS Europe Spa became a whollyowned subsidiary. The reverse merger of CFS Antioxidnates De Mexico De CV with Dresen Quimica SAPI De CV was effective 31st January, 2019 and resultant to reverse merger, CFS Antioxidantes De Mexico S.A. de. C.V. ceased to be the whollyowned subsidiary of the Company from the aforementioned date. As a part of this initiative, Company acquired a company situated in Southern part of India, namely, AlgalR Nutrapharms Private Limited (AlgalR) which manufactures oils containing Omega 3 Fatty Acids. The company embarked upon its largest greenfield expansion in 2018 in Dahej, Gujarat for a greentechnologybased DiPhenol plant for a 10,000 MT DiPhenol facility. And in September 2020, it announced the commercial production of Hydroquinone and Catechol.During the financial year 202122, AlgalR NutraPharms Private Limited and CFS De Mexico Blends SAPI De CV became subsidiaries and Fine Lifestyle Brands Limited has ceased to be a Associate of the Company.The Company initiated the commercial production of Vanillin and Ethyl Vanillin in Dahej in January, 2023 in FY 2024.The Company acquired a 49% equity stake in Clean Max Sundarban Private Limited, making it an associate of the Company in FY 2026. During FY26, Company expanded Xtendra, NaSure and Ezentail platforms across food functional ingredients. The farm level performance solutions have increased during the year 2026. During the year 2026, the Company prioritised scaling up Adorr Vanillin Premium in key export markets.

Camlin Fine Sciences Financial Highlights


For the full year FY2026–2027, revenue reached ₹1752.1 crore and profit touched at ₹-33.19 crore. As of Jun '26, Camlin Fine Sciences’s market capitalisation stood at ₹1,953.24 crores. Shareholding as of Jun '26 shows promoters holding 48%, with FIIs at 0.9%, DIIs at 5.4%, and public at 45.6%.
Camlin Fine Sciences SIP Returns Calculator
5,000
Over the past
Total Investment of ₹3,00,000
Monthly SIP of 5,000 would have become 2,39,460 in 5 years with a gain of -60,539 (-20.18%)
Camlin Fine Sciences Fundamental

Market Cap (in crs)

1,953.24

Face Value

1

Turnover (in lacs)

395.35

Key Metrics

Qtr Change %
56.73% Fall from 52W High
-25.6
Dividend yield 1yr %
0

Camlin Fine Sciences Key Financials

View more
Use arrow keys to navigate between tabs, Enter or Space to select, Home and End to go to first or last tab.
Use arrow keys to navigate between tabs, Enter or Space to select, Home and End to go to first or last tab.
Loading chart...
Camlin Fine Sciences Result Highlights
  • Camlin Fine Sciences reported a 0.1% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 12.2%.

  • Its expenses for the quarter were up by 1.5% QoQ and 9.1% YoY.

  • The net profit decreased 93.6% QoQ and decreased 47.6% YoY.

  • The earnings per share (EPS) of Camlin Fine Sciences declined at 0.2 during Q3FY25.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Camlin Fine Sciences Technical Analysis

Moving Averages Analysis
101.68
Current Price
Bullish Moving Averages
0
Bearish Moving Averages
16
Use arrow keys to navigate between tabs, Enter or Space to select, Home and End to go to first or last tab.
5 EMA
102.80
10 EMA
103.50
12 EMA
103.90
20 EMA
106.30
26 EMA
108.10
50 EMA
113.90
100 EMA
121.40
200 EMA
134.90

Delivery & Volume

Loading chart...

Day

53.10%

Week

47.20%

Month

31.80%

101.74
Pivot
Resistance
First Resistance
102.59
Second Resistance
103.50
Third Resistance
104.35
Support
First Support
100.83
Second support
99.98
Third Support
99.07
Relative Strength Index
35.94
Money Flow Index
32.51
MACD
-4.22
MACD Signal
-4.84
Average True Range
4.15
Average Directional Index
29.32
Rate of Change (21)
-4.49
Rate of Change (125)
-28.71
Compare

Camlin Fine Sciences Shareholding Pattern

Use arrow keys to navigate between tabs, Enter or Space to select, Home and End to go to first or last tab.
Promoter
48%
Foreign Institutions
0.9%
Mutual Funds
5.1%
Domestic Institutions
5.4%
Public
45.6%
Camlin Fine Sciences Latest News
09 SEP 2026
17 AUG 2026
12 AUG 2026

Camlin Fine Sciences share price is ₹101.68 in NSE and ₹101.8 in BSE as on 11/9/2026.

Camlin Fine Sciences share price in the past 1-year return was -55.02. The Camlin Fine Sciences share hit a 1-year low of Rs. 96.21 and a 1-year high of Rs. 235.

The market cap of Camlin Fine Sciences is Rs. 1953.24 Cr. as of 11/9/2026.

The PE ratios of Camlin Fine Sciences is -56.56 as of 11/9/2026.

The PB ratios of Camlin Fine Sciences is 2.11 as of 11/9/2026

The Mutual Fund Shareholding in Camlin Fine Sciences was 5.12% at the end of 11/9/2026.

You can easily buy Camlin Fine Sciences shares in Kotak Neo by opening a demat account and getting the KYC documents verified online.

The 52-week high and low of Camlin Fine Sciences share price is ₹235 and ₹96.21 as of 11/9/2026.

Please be aware that Camlin Fine Sciences stock prices are subject to continuous fluctuations due to various factors.